Mesalazine liquid enema    (DrugBank: Mesalazine)

1 disease
IDDisease name (Link within this page)Number of trials
97Ulcerative colitis1

97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,269 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00737789
(ClinicalTrials.gov)
November 200819/8/2008Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.Multicentre, Controlled, Randomised, Investigator-Blinded, Comparative Study of Oral Mesalazine 4g Once Daily Versus Mesalazine 4g in Two Divided Doses in Patients With Active Ulcerative Colitis.Ulcerative ColitisDrug: Mesalazine slow-release granules;Drug: Mesalazine liquid enemaFerring PharmaceuticalsNULLCompleted18 YearsN/ABoth206Phase 3Belgium;France;Netherlands;United Kingdom